Recent news on Mesylate

Pergolide Gourmeds  -  25 May 2007
PR Newswire (press release),SWEDESBORO, NJ, May 24 /PRNewswire/ -- The March 29 voluntary withdrawal of pergolide mesylate, a drug used to treat Parkinson's disease,

Oscient Pharmaceuticals Reports Financial Results for First ...  -  May 2, 2007
PharmaLive.com (press release),The Company also recorded approximately $11.0 million in revenues related to FACTIVE(R) (gemifloxacin mesylate) tablets, compared to $9.2 million in the

Tablets for Five-Day Treatment of Community-Acquired Pneumonia  -  May 9, 2007
Pharmaceutical Processing,The FDA has approved Oscient Pharmaceuticals' FACTIVE® (gemifloxacin mesylate) tablets for the five-day treatment of community-acquired pneumonia of mild to

Antidepressants linked to suicide risk in young adults  -  May 5, 2007
Food Consumer,Paxil (paroxetine HCl), Pexeva (paroxetine mesylate), Prozac (fluoxetine HCl), Remeron (mirtazapine), Sarafem (fluoxetine HCl), Seroquel (quetiapine),

Pergolide Availability: No FDA Announcement, Supplies Running Low  -  May 4, 2007
TheHorse.com,More than a month since pergolide mesylate, a drug commonly used to treat pituitary pars intermedia dysfunction (PPID), also known as equine Cushing's

Pfizer Launches New Cancer Treatment In NZ  -  May 3, 2007
Scoop.co.nz,...cell carcinoma (RCC) and gastrointestinal stromal tumour (GIST), after the failure of imatinib mesylate treatment due to resistance or intolerance.

Oscient Pharmaceuticals Announces Successful Convertible Debt ...  -  26 Apr 2007
Business Wire (press release),FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Novartis case: arguments end  -  Mar 28, 2007
Hindu,...commenced hearing on the statutory appeal of the company against the rejection of its application to patent beta crystalline form of imatinib mesylate,

Novartis case: HC hears appeal  -  Mar 28, 2007
Chennai Online,...filed by the firm challenging rejection of its application for patenting beta crystalline form of Imatinib Mesylate under Section 3(d) of the Act.

Govt defends stance in Novartis patent suit  -  Mar 27, 2007
Daily News & Analysis,...against the rejection of its patent application for beta crystalline form of imatinib mesylate and also challenging section 3 (d) of the Patents Act,

Positive Results Prompt US National Cancer Institute to Make ...  -  Apr 12, 2007
PR Newswire (press release),About Gleevec Gleevec(R) (imatinib mesylate) is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant

Gleevec available to patients in post-surgical GIST study  -  Apr 15, 2007
News-Medical.net,Investigators will begin offering Gleevec (imatinib mesylate) tablets to patients receiving placebo in a major North American clinical trial after an

Gleevec Decreases Cancer Recurrence for Patients with Primary ...  -  Apr 13, 2007
PressZoom (press release),...a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec ®) after complete removal

Positive Results Prompt US National Cancer Institute to Make ...  -  Apr 12, 2007
Earthtimes.orgEAST HANOVER, NJ, April 12 -- Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North

Oscient Pharmaceuticals Provides Preliminary Revenue Results for ...  -  Apr 11, 2007
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Health Canada approves SPRYCEL(TM), a new treatment for chronic ...  -  Mar 28, 2007
CNW Telbec (Communiqués de presse),...of adults with chronic, accelerated or blast phase CML who fail or are intolerant to prior therapy including imatinib mesylate (marketed as Gleevec(R)).

The Fred Hutchinson Cancer Research Center Adopts the BioMark ...  -  Apr 19, 2007
Genetic Engineering News (press release),...single base pair mutations that develop in the ABl kinase domain in CML cells, which often cause resistance to imatinib mesylate (drug therapy).

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC ...  -  Apr 18, 2007
PharmaLive.com (press release),Other tyrosine kinases are important in cell signaling and have been targets for other drugs such as imatanib mesylate (Gleevec(R)), which is approved for

Keeping the atmosphere — and the mind — calm  -  Apr 18, 2007
Ithaca Journal,These items are adorned with zippy company drug names like “Anzemet (dolasetron mesylate injection/tablets),� “Neulasta (pegfilgrastim),� “Sanofi Aventis,�

Pergolide: Veterinarians, Horse Owners Fighting for Availability  -  Apr 17, 2007
TheHorse.com,Pergolide mesylate, a drug commonly used to treat pituitary pars intermedia dysfunction (PPID), also known as equine Cushing's disease, has been withdrawn

INNOVIVE Pharmaceuticals Announces Interim Phase I Data on INNO ...  -  Apr 16, 2007
Genetic Engineering News (press release),1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth

Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors  -  Apr 16, 2007
MedIndia,...placebo-controlled clinical trial for patients with primary GIST, showed that patients who received imatinib mesylate (Gleevec) after complete removal

OHSU Cancer Institute, 1 Of Largest In GIST Study And Gleevec  -  Apr 15, 2007
Medical News Today (press release),...placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST) showed that patients who received imatinib mesylate

Gleevec decreases cancer recurrence for GIST  -  Apr 15, 2007
News-Medical.net,...a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec) after complete removal of

Illumina Shuttering Connecticut Plant, Relocating 50 Employees  -  Apr 15, 2007
San Diego Business Journal,The active ingredient in NV-101 is phentolamine mesylate, which has been used for more than 50 years in other medical indications at significantly higher

Gleevec reduces recurrence in colon cancer  -  Apr 14, 2007
Cancerfacts.com,The pill, sold as Gleevec®(imatinib mesylate) in the US and as Glivec® outside the US, was first approved by the FDA in 2001 for treatment of chronic

Health Highlights: April 13, 2007  -  Apr 13, 2007
Atlanta Journal Constitution (subscription),People who took the drug Gleevec (imatinib mesylate) after having a particular type of gastrointestinal tumor removed were significantly less likely to have

Gleevec Decreases Recurrence for Patients With Primary ...  -  Apr 13, 2007
DG News...a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec {R}) after complete

Gleevac found to dramatically reduce cancer recurrence risk  -  Apr 13, 2007
DailyIndia.com,The efficacy of imatinib mesylate (Gleevec) in preventing a recurrence of gastrointestinal stromal tumour (GIST) was observed during a placebo-controlled

Gleevac found to dramatically reduce cancer recurrence risk  -  Apr 13, 2007
South Asian Women's Forum,The efficacy of imatinib mesylate (Gleevec) in preventing a recurrence of gastrointestinal stromal tumor (GIST) was observed during a placebo-controlled

National Cancer Institute to Make Gleevec® Available to Patients ...  -  Apr 12, 2007
EndoNurse,EAST HANOVER, NJ -- Investigators will begin offering Gleevec® (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical

Novalar Pharmaceuticals submits NDA for dental anesthetic reversal ...  -  Apr 12, 2007
News-Medical.net,Phentolamine mesylate (a vasodilator), the active ingredient in the investigational agent NV-101, has been approved and in use in specific medical

Contract win with Novartis Canada  -  Apr 10, 2007
Laboratory Talk,These services involve Novartis's blood level monitoring programme for Gleevec (imatinib mesylate), a medication approved for the treatment of patients with

PWRM: Files Utility Patent Application for Resistance Test w ...  -  Apr 10, 2007
Therapeutics Daily (subscription) (press release),The patent application covers a test, a drug target and therapeutic design specifications with the potential to overcome resistance to imatinib mesylate

Warnex to Perform LC/MS and PCR Services for Pharmacogenetic Study ...  -  Apr 6, 2007
MassSpec.net (press release),These services involve Novartis' Blood Level Monitoring Program for Gleevec® (imatinib mesylate), a medication approved for the treatment of patients with

Warnex to perform pharmacogenetic and bioanalytical services for ...  -  Apr 5, 2007
CNW Telbec (Communiqués de presse),These services involve Novartis' Blood Level Monitoring Program for Gleevec(R) (imatinib mesylate), a medication approved for the treatment of patients with

Novartis plea shifted to appellate board  -  Apr 5, 2007
Chennai Online,...by Novartis to challenge the rejection of its application for patenting beta crystalline form of "imatinib mesylate" under Section 3(d) of the Act.

Wockhardt moves HC for patent law  -  Apr 3, 2007
Economic Times,...came a few months after it rejected Novartis’ patent application for anti-cancer drug Glivec (known by its generic name, imatinib mesylate).

ChemGenex Announces Initiation of Second Phase 2/3 Clinical Trial ...  -  Apr 3, 2007
Genetic Engineering News (press release),CML patients routinely receive treatment with imatinib mesylate (Gleevec(R)) and dasatinib (Sprycel(R)), TKIs that are approved in both the United States

ChemGenex Announces Initiation of Second Phase 2/3 Clinical Trial ...  -  Apr 3, 2007
Business Wire (press release),CML patients routinely receive treatment with imatinib mesylate (Gleevec ® ) and dasatinib (Sprycel ® ), TKIs that are approved in both the United States

MAP Pharmaceuticals Reports Positive Phase 2 Results for its ...  -  Apr 3, 2007
Drug Newswire (press release),By providing rapid onset with a novel formulation of a proven compound (dihydroergotamine mesylate), MAP Pharmaceuticals seeks to meet the treatment needs

Parkinson's drug withdrawn  -  Mar 30, 2007
CBC Manitoba,Pergolide mesylate, sold under the brand name Permax by Eli Lilly and Co., is in a class of drugs called dopamine agonists, which stimulate the brain

Permax Pulled from the Market  -  Mar 29, 2007
Lawyers and Settlements,Permax (Generic name: pergolide mesylate), manufactured by Eli Lilly, has been prescribed to millions of people since it was approved in 1989 to treat

`Process of grant or rejection of patent is a quasi-judicial function'  -  Mar 27, 2007
Hindu,When a batch of petitions filed by Novartis against the refusal to patent its beta crystalline form of imatinib mesylate came up for hearing before a

Oscient Pharmaceuticals Commences Exchange Offers  -  Mar 29, 2007
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Oscient Pharmaceuticals Commences Exchange Offers  -  Mar 29, 2007
Business Wire (press release),FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Pfizer's Sutent® Achieves First Line Recommendation For Treatment ...  -  27 Mar 2007
Medical News Today (press release),...and/or metastatic malignant gastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance.

Novartis: patents provision bereft of guidelines  -  27 Mar 2007
Hindu,The impugned order, turning down Novartis' patent application for beta crystalline form of imatinib mesylate, itself said the product had 30 per cent of

The Cost of Clinical Trials  -  Mar 20, 2007
Drug Discovery & Development,Gemin X begins recruiting patients for its phase I trial, Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological

FDA denies Lilly’s appeal of its ruling necessitating additional ...  -  Mar 16, 2007
OSN SuperSite (subscription),The US Food and Drug Administration has denied Eli Lilly's appeal of the agency's ruling requiring an additional 3-year study of ruboxistaurin mesylate

Madras HC to rule on Novartis’ patent case  -  Mar 5, 2007
Economic Times,However, Glivec (generic name: Imatinib mesylate) is not an incremental innovation and is not either a case of evergreening. “Glivec is a new drug,

CORRECTED: Webcast Alert: Oscient Pharmaceuticals to Present at ...  -  Mar 8, 2007
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Interruption of Treatment with Gleevec® Not Recommended for GIST  -  Mar 23, 2007
Cancer Consultants (press release),According to an article published in the Journal of Clinical Oncology, interruption in treatment with Gleevec® (imatinib mesylate) is not recommended for

PAREXEL To Offer Significant Industry Insights At 19th Annual Drug ...  -  Mar 22, 2007
PR Newswire (press release),Director, PAREXEL Consulting (09:00 - 10:30) -- Residues of Genotoxic Alkyl Mesylates in Mesylate Salt Drug substances: Real or Imaginary Problems?

Sutent achieves first line EAU approval for kidney cancer  -  Mar 22, 2007
SpiritIndia,...and/or metastatic malignantgastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due toresistance or intolerance.

Sutent achieves first line EAU approval for kidney cancer  -  Mar 22, 2007
HULIQ,...and/or metastatic malignant gastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance.

Targeted Renal Therapy for Patients at Risk for Contrast-Induced ...  -  Mar 5, 2007
Business Wire (press release),Agents infused using TRT included: fenoldopam mesylate (92.5 percent of patients), sodium bicarbonate (4.7 percent), alprostadil (2.8 percent) and

Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in ...  -  Mar 2, 2007
CNW Telbec (Communiqués de presse),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved in the US for the five-day treatment of acute bacterial exacerbations of chronic

NOVALAR Presents Results From Successful Studies Of Anesthetic ...  -  Mar 21, 2007
Medical News Today (press release),Phentolamine mesylate (a vasodilator), the active ingredient in the investigational agent NV-101, has been approved and in use in specific medical

US patents for improved drugs get tougher  -  Mar 15, 2007
Economic Times,...the Swiss drug giant has sought patent protection in India for a crystalline form of iminitab mesylate (Glivec’s active ingredient).

Oscient Pharmaceuticals Files Registration Statements for Proposed ...  -  Mar 15, 2007
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Oscient Pharmaceuticals Files Registration Statements for Proposed ...  -  Mar 15, 2007
Business Wire (press release),FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Dead Man Walking  -  Mar 9, 2007
Times of India,Chances are you have never heard of the drug, imatinib mesylate, let alone Section 3 (d) of India's Patent Amendment Act of 2005.

'Biomarkers will provide a dynamic approach'  -  Mar 8, 2007
Express Pharma,For exampletrastuzumab (Genentech's Herceptin), imatinib mesylate (Novartis's Gleevec), and cetuximab (ImClone's Erbitux). Besides Biocon, Dr Reddy's Labs

Novartis: court poses queries on core grounds of challenge  -  Mar 5, 2007
Hindu,The writ petitions are against the rejection of an application to patent Novartis' beta crystalline form of imatinib mesylate, by an order dated January 25,

MAP Pharmaceuticals Reports Positive Phase 2 Results For Its ...  -  Mar 2, 2007
Medical News Today (press release),By providing rapid onset with a novel formulation of a proven compound (dihydroergotamine mesylate), MAP Pharmaceuticals seeks to meet the treatment needs

Senetek PLC Announces Clinical Update on Invicorp(R)  -  Mar 1, 2007
Drug Newswire (press release),Invicorp(R) is a patented injectable combination of phentolamine mesylate and vasoactive intestinal polypeptide. Clinical data indicate that the efficacy

Two-gene Test Correctly Distinguishes GIST from Leiomyosarcoma  -  Feb 28, 2007
Cancer Consultants (press release),...treatment for GIST typically includes surgical removal of as much cancer as possible and treatment with the targeted agent Gleevec® (imatinib mesylate).

Group Purchasing Organization Expands Ability to Participate in ...  -  Feb 28, 2007
Atlantic Information Services, Inc.,He says that cancer therapy Gleevec (imatinib mesylate) is a good example: "They stopped the trial early and put all the participants on the therapy"

'Patent Act amendment can't be queried'  -  Feb 24, 2007
Chennai Online,...giant Novartis AG, challenging rejection of its application for patenting beta crystalline form of Imatinib Mesylate under section 3(d) of the Act.

Novartis' charges against Indian patent law refuted  -  Feb 22, 2007
Moneycontrol.com,...for beta crystalline form of imatinib mesylate, Mr Gopalan said that there was nothing in the provisions of the Act which could be said to be arbitrary.

India: Patent Protection As An ‘Incentive For Innovation’  -  Feb 21, 2007
Mondaq News Alerts (subcription),Novartis’ invention of Glivec is prior to 1995, however, the company had filed a new patent on the crystalline form of Imatinib mesylate (Glivec’s active

New Treatment Guidelines for Community-Acquired Pneumonia ...  -  Feb 22, 2007
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Waxman, EU Parliamentarians join agitation against Novartis  -  Feb 14, 2007
Business Standard,It is also challenging a decision of the Indian patent office to reject a patent to its blockbuster blood cancer drug Glivec (Imatinib Mesylate).

Cardiac Events with Gleevec  -  Feb 13, 2007
eMaxHealth.com,Novartis is notifying healthcare professionals about new precautions for Gleevec (imatinib mesylate). Gleevec is used to treat certain patients with chronic

New Indication Approved for Sutent  -  Feb 12, 2007
Facts and Comparisons,Sutent is also indicated for the treatment of gastrointestinal stromal tumors after disease progression on or intolerance to, imatinib mesylate.

Novartis challenges Patents Act provision  -  Jan 29, 2007
Economic Times,Novartis is hopeful that the hurdles in the patent law in its current form will be removed and that the patent for Imatinib mesylate will be granted,� told

Drug major moves court  -  Jan 29, 2007
Hindu,...application for beta crystalline form of imatinib mesylate, as well as the provisions of the Patents (Amendment) Act 2005 under which it was rejected.

Amendment to Patents Act defended  -  Feb 22, 2007
Chennai Online,...filed by Novartis challenging the rejection of its application for patenting beta crystalline form of Imatinib Mesylate under section 3(d) of the Act.

Clinical Data Supporting Development of ChemGenex’s Ceflatonin ...  -  Feb 14, 2007
Business Wire (press release),...patients who had failed treatment with Gleevec ® (imatinib mesylate) have been published in Cancer (the journal of the American Cancer Society).

Rejecting patents on chemical derivatives is tantamount to "fatwa ...  -  Feb 16, 2007
Hindu,When a batch of petitions filed by Novartis AG against the rejection of its patent application for beta crystalline form of imatinib mesylate came up for

Amendment to Patents Act questioned  -  Feb 16, 2007
Chennai Online,...pharmaceutical major Novartis AG, challenging the rejection of its application for patenting beta crystalline form of Imatinib Mesylate.

The pharmaceutical giant takes the government to court for not ...  -  Feb 16, 2007
Tehelka (subscription),The government rejected the patent application for the cancer drug Imatinib mesylate, marketed under the brand name Gleevec/Glivec in many countries to

Opposition Gains Support Against Novartis Patent Lawsuit In India  -  Feb 15, 2007
Intellectual Property Watch,The Novartis spokesperson told Intellectual Property Watch that this is not a case about access to medicines as the cancer drug, Gleevec (imatinib mesylate)

Pfizer's Sutent Receives FDA Approval To Include New First-Line ...  -  Feb 9, 2007
Medical News Today (press release),Sutent is also indicated for the treatment of gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib mesylate.

Taking TRIPS to India — Novartis, Patent Law, and Access to Medicines  -  Feb 7, 2007
New England Journal of Medicine (subscription),India, to protest the company's efforts to obtain an Indian patent on Gleevec, the company's brand-name version of imatinib mesylate.

Cancer drug patent woes mount for Novartis  -  Feb 4, 2007
Daily News & Analysis,Novartis had filed an appeal challenging the rejection of its patent application for leukemia drug Gleevec (imatinib mesylate) by the Madras patent office

Patents and Public Health Crisis Moves Center-Stage  -  Feb 1, 2007
Huffington Post,And, cancer patients who suffer from Chronic Myeloid Leukemia could lose access to Gleevec (imatinib mesylate) because of the patent case filed by Novartis

Buy Dishman Pharma with target of Rs 286: India Infoline  -  Jan 31, 2007
Moneycontrol.com,Sales for EM (Eposartan Mesylate) to Solvay are back on track after a sluggish H1 FY07 and on target to record Rs1bn for FY07. Operating profit margin (OPM)

Many lives at risk if drug company wins court case  -  Jan 29, 2007
Daily Nation (subscription),In January 2006, this section was used by India’s Patent office to reject a patent application by Novartis for a cancer drug, imaninib mesylate,

Novartis questions Indian patent law provisions  -  Jan 30, 2007
Earthtimes.orgNovartis had invented Glivec prior to 1995, but it has filed for a new patent for the chrystalline form of Imatinib mesylate (Glivec's active ingredient),

2006 drug approvals: finding the niche  -  Feb 1, 2007
Nature.com (subscription),Meanwhile, Eli Lilly will be hoping for approval of its diabetic retinopathy drug, ruboxistaurin mesylate (Arxxant). It's likely to be another good year for

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional